@inproceedings{inproceedings, title  = {{Determinants of response of HER2+gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)}},

 url = {{}},

 year = {{2019}},

 month = {{10}},

 author = {{Park H and Uronis H and Kang Y-K and Ng MCH and Enzinger P and Lee KW and Rutella S and Church SE and Nordstrom J and Knutson K and Erskine C et al}},

 volume = {{30}},

 journal = {{ANNALS OF ONCOLOGY}},

 pages = {{485-485}},

 note = {{Accessed on 2026/02/25}}}